-
1
-
-
0031963294
-
Cancer statistics, 1998
-
Landis SH, Murray T, Bolden S, et al: Cancer statistics, 1998. CA Cancer J Clin 48:1, 1998.
-
(1998)
CA Cancer J Clin
, vol.48
, pp. 1
-
-
Landis, S.H.1
Murray, T.2
Bolden, S.3
-
2
-
-
0003405566
-
SEER cancer statistics review 1973-1990
-
Miller B, Ries L, Hankey B (eds): Bethesda, National Institutes of Health
-
Hankey B, Brinton L, Kessler L, et al: SEER cancer statistics review 1973-1990, in Miller B, Ries L, Hankey B (eds): National Institutes of Health Publication, pp 93-278. Bethesda, National Institutes of Health, 1993.
-
(1993)
National Institutes of Health Publication
, pp. 93-278
-
-
Hankey, B.1
Brinton, L.2
Kessler, L.3
-
3
-
-
0029981617
-
Chemotherapy for advanced breast cancer: A current perspective
-
Seidman AD: Chemotherapy for advanced breast cancer: A current perspective. Semin Oncol 23(suppl 2):55-59, 1996.
-
(1996)
Semin Oncol
, vol.23
, Issue.2 SUPPL.
, pp. 55-59
-
-
Seidman, A.D.1
-
4
-
-
0001025201
-
Principles in the management of metastatic disease
-
Harris JR, Henderson IC, Hellman S, et al (eds): Philadelphia, Lippincott
-
Henderson IC, Harris JR: Principles in the management of metastatic disease, in Harris JR, Henderson IC, Hellman S, et al (eds): Breast Diseases, 2nd ed, pp 547-665. Philadelphia, Lippincott, 1991.
-
(1991)
Breast Diseases, 2nd Ed
, pp. 547-665
-
-
Henderson, I.C.1
Harris, J.R.2
-
5
-
-
0032423157
-
Combination chemotherapy vs single-agent therapy as first- and second-line treatment in metastatic breast cancer: A prospective randomized trial
-
Joensuu H, Holli K, Heikkinen M, et al: Combination chemotherapy vs single-agent therapy as first- and second-line treatment in metastatic breast cancer: A prospective randomized trial. J Clin Oncol 16:3720-3730, 1998.
-
(1998)
J Clin Oncol
, vol.16
, pp. 3720-3730
-
-
Joensuu, H.1
Holli, K.2
Heikkinen, M.3
-
6
-
-
0004663288
-
Taxotere improves survival over mitomycin-C vinblastine in patients with metastatic breast cancer who have failed an anthracycline-containing regimen: Final results of a phase III randomized trial
-
Nabholtz, JM, Thuerlimann B, Beswoda WR, et al: Taxotere improves survival over mitomycin-C vinblastine in patients with metastatic breast cancer who have failed an anthracycline-containing regimen: Final results of a phase III randomized trial (abstract). Proc Am Soc Clin Oncol 17:101a, 1998.
-
(1998)
Proc Am Soc Clin Oncol
, vol.17
-
-
Nabholtz, J.M.1
Thuerlimann, B.2
Beswoda, W.R.3
-
7
-
-
0002088796
-
Phase III trial of doxorubicin vs paclitaxel vs doxorubicin + paclitaxel as first-line therapy for metastatic breast cancer: An intergroup trial
-
Sledge GW, Neuberg D, Ingle J, et al: Phase III trial of doxorubicin vs paclitaxel vs doxorubicin + paclitaxel as first-line therapy for metastatic breast cancer: An intergroup trial (abstract). Proc Am Soc Clin Oncol 16:1a, 1997.
-
(1997)
Proc Am Soc Clin Oncol
, vol.16
-
-
Sledge, G.W.1
Neuberg, D.2
Ingle, J.3
-
8
-
-
0000673570
-
Standard vs accelerated intensified CEF in metastatic breast cancer patients: Results from MIG-3 randomized study
-
Lionetto R, Venturini M, Del Mastro L, et al: Standard vs accelerated intensified CEF in metastatic breast cancer patients: Results from MIG-3 randomized study (abstract). Proc Am Soc Oncol 17:111a, 1998.
-
(1998)
Proc Am Soc Oncol
, vol.17
-
-
Lionetto, R.1
Venturini, M.2
Del Mastro, L.3
-
9
-
-
0026594645
-
Autologous bone marrow transplantation for breast cancer
-
Peters WP: Autologous bone marrow transplantation for breast cancer. Curr Opin Oncol 4: 279-282, 1992.
-
(1992)
Curr Opin Oncol
, vol.4
, pp. 279-282
-
-
Peters, W.P.1
-
10
-
-
0027732664
-
High intensity chemotherapy with hematopoietic support in breast cancer
-
Crown J, Vahdat L, Fennelly D, et al: High intensity chemotherapy with hematopoietic support in breast cancer. Ann NY Accad Sci 1:378-388, 1993.
-
(1993)
Ann NY Acad Sci
, vol.1
, pp. 378-388
-
-
Crown, J.1
Vahdat, L.2
Fennelly, D.3
-
11
-
-
0029116891
-
High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: A randomized trial
-
Bezwoda WR, Seymour L, Dansey RD, et al: High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: A randomized trial. J Clin Oncol 13:2483-2489, 1995.
-
(1995)
J Clin Oncol
, vol.13
, pp. 2483-2489
-
-
Bezwoda, W.R.1
Seymour, L.2
Dansey, R.D.3
-
12
-
-
26344474783
-
Single vs tandem high-dose chemotherapy with stem-cell support for chemotherapy-sensitive metastatic breast cancer: First results from an ongoing multicenter phase III trial
-
Frick M, Kroeger N, Adomeit A, et al: Single vs tandem high-dose chemotherapy with stem-cell support for chemotherapy-sensitive metastatic breast cancer: First results from an ongoing multicenter phase III trial (abstract). Proc Am Soc Clin Oncol 17:141a, 1998.
-
(1998)
Proc Am Soc Clin Oncol
, vol.17
-
-
Frick, M.1
Kroeger, N.2
Adomeit, A.3
-
13
-
-
26344450003
-
Tandem and triple high-dose chemotherapy with autologous peripheral blood stem-cell support in patients with metastatic breast cancer
-
Huober J, Schneeweiss A, Fersis N, et al: Tandem and triple high-dose chemotherapy with autologous peripheral blood stem-cell support in patients with metastatic breast cancer (abstract). Proc Am Soc Clin Oncol 17:146a, 1998.
-
(1998)
Proc Am Soc Clin Oncol
, vol.17
-
-
Huober, J.1
Schneeweiss, A.2
Fersis, N.3
-
14
-
-
0032529660
-
Paclitaxel-induced apoptosis is associated with expression and activation of c-mos gene product in human ovarian carcinoma SKOV3 cells
-
Ling HY, Yang Y, Tornos C, et al: Paclitaxel-induced apoptosis is associated with expression and activation of c-mos gene product in human ovarian carcinoma SKOV3 cells. Cancer Res 58:3633-3640, 1998.
-
(1998)
Cancer Res
, vol.58
, pp. 3633-3640
-
-
Ling, H.Y.1
Yang, Y.2
Tornos, C.3
-
15
-
-
0032529464
-
Mechanisms of Taxol-induced cell death are concentration dependent
-
Torres K, Horwitz SB: Mechanisms of Taxol-induced cell death are concentration dependent. Cancer Res 58:3620-3626, 1998.
-
(1998)
Cancer Res
, vol.58
, pp. 3620-3626
-
-
Torres, K.1
Horwitz, S.B.2
-
16
-
-
0027238859
-
Cell kill kinetics and cell cycles effects of Taxol on human and hamster ovarian cell lines
-
Lopes NM, Adams EF, Pitts TW, et al: Cell kill kinetics and cell cycles effects of Taxol on human and hamster ovarian cell lines. Cancer Chemother Pharmacol 32:235-242, 1993.
-
(1993)
Cancer Chemother Pharmacol
, vol.32
, pp. 235-242
-
-
Lopes, N.M.1
Adams, E.F.2
Pitts, T.W.3
-
17
-
-
0030020158
-
Mitotic block induced in HeLa cells by low concentrations of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death
-
Jordan MA, Wendell K, Gardiner S, et al: Mitotic block induced in HeLa cells by low concentrations of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death. Cancer Res 56:816-825, 1996.
-
(1996)
Cancer Res
, vol.56
, pp. 816-825
-
-
Jordan, M.A.1
Wendell, K.2
Gardiner, S.3
-
18
-
-
0029946928
-
Ninety-six hour paclitaxel infusion after progression during short taxane exposure: A phase: II pharmacokinetic and pharmacodynamic study in patients with metastatic breast cancer
-
Seidman AD, Hochhauser D, Gollub M, et al: Ninety-six hour paclitaxel infusion after progression during short taxane exposure: A phase: II pharmacokinetic and pharmacodynamic study in patients with metastatic breast cancer. J Clin Oncol 14:1877-1884, 1996.
-
(1996)
J Clin Oncol
, vol.14
, pp. 1877-1884
-
-
Seidman, A.D.1
Hochhauser, D.2
Gollub, M.3
-
19
-
-
0029012127
-
Paclitaxel by 3-hour infusion followed by 96-hour infusion on failure in patients with refractory malignant disease
-
Chang AY, Boros L, Garrow R, et al: Paclitaxel by 3-hour infusion followed by 96-hour infusion on failure in patients with refractory malignant disease. Semin Oncol 22(suppl ):124-127, 1995.
-
(1995)
Semin Oncol
, vol.22
, Issue.SUPPL.
, pp. 124-127
-
-
Chang, A.Y.1
Boros, L.2
Garrow, R.3
-
20
-
-
8944245005
-
Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer
-
Nabholtz JM, Gelmon K, Bontenbal M, et al: Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Oncol 14:1858-1867, 1996.
-
(1996)
J Clin Oncol
, vol.14
, pp. 1858-1867
-
-
Nabholtz, J.M.1
Gelmon, K.2
Bontenbal, M.3
-
21
-
-
0001261990
-
Failure of higher dose paclitaxel to improve outcome in patients with metastatic breast cancer - Results from CALGB 9342
-
Winer E, Berry D, Duggan D, et al: Failure of higher dose paclitaxel to improve outcome in patients with metastatic breast cancer - results from CALGB 9342 (abstract). Proc Am Soc Clin Oncol 17:101a, 1998.
-
(1998)
Proc Am Soc Clin Oncol
, vol.17
-
-
Winer, E.1
Berry, D.2
Duggan, D.3
-
22
-
-
0000228951
-
Final results: Randomized phase III trial of paclitaxel by 3-hr vs 96-hr infusion in patients with metastatic breast cancer: the long and short of it
-
Holmes FA, Valero V, Buzdar AU, et al: Final results: Randomized phase III trial of paclitaxel by 3-hr vs 96-hr infusion in patients with metastatic breast cancer: The long and short of it (abstract). Proc Am Soc Clin Oncol 17:110a, 1998.
-
(1998)
Proc Am Soc Clin Oncol
, vol.17
-
-
Holmes, F.A.1
Valero, V.2
Buzdar, A.U.3
-
23
-
-
0000386968
-
A multicenter randomized study of two schedules of paclitaxel in patients with advanced breast cancer
-
Peretz T, Sulkes A, Chollet P, et al: A multicenter randomized study of two schedules of paclitaxel in patients with advanced breast cancer. Eur J Cancer 31A (suppl 5):S75, 1995.
-
(1995)
Eur J Cancer
, vol.31 A
, Issue.5 SUPPL.
-
-
Peretz, T.1
Sulkes, A.2
Chollet, P.3
-
24
-
-
0000362869
-
Effect of Taxol duration of infusion in advanced breast ca: Results from NSABP-B26 trial comparing 3- to 24-hr infusion of high-dose Taxol
-
Mamounas E, Brown A, Smith R, et al: Effect of Taxol duration of infusion in advanced breast ca: Results from NSABP-B26 trial comparing 3- to 24-hr infusion of high-dose Taxol (abstract). Proc Am Soc Clin Oncol 17:101a, 1998.
-
(1998)
Proc Am Soc Clin Oncol
, vol.17
-
-
Mamounas, E.1
Brown, A.2
Smith, R.3
-
25
-
-
0031757277
-
Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer
-
Seidman AD, Hudis CA, Albanel J, et al: Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. J Clin Oncol 16:3353-3361, 1998.
-
(1998)
J Clin Oncol
, vol.16
, pp. 3353-3361
-
-
Seidman, A.D.1
Hudis, C.A.2
Albanel, J.3
-
26
-
-
0027494879
-
Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients
-
Huizing MT, Keung ACF, Rosing H, et al: Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients. J Clin Oncol 11:2127-2135, 1997.
-
(1997)
J Clin Oncol
, vol.11
, pp. 2127-2135
-
-
Huizing, M.T.1
Keung, A.C.F.2
Rosing, H.3
-
27
-
-
0038313647
-
Phase II trial multicenter of a weekly Taxol, 5-fluorouracil and leucovorin regimen in patients with metastatic breast cancer
-
Loesch DM, Robert NJ, Keller AM, et al: Phase II trial multicenter of a weekly Taxol, 5-fluorouracil and leucovorin regimen in patients with metastatic breast cancer (abstract). Proc Am Soc Clin Oncol 17:155a, 1998.
-
(1998)
Proc Am Soc Clin Oncol
, vol.17
-
-
Loesch, D.M.1
Robert, N.J.2
Keller, A.M.3
-
28
-
-
4243246767
-
Losoxantrone + paclitaxel vs paclitaxel alone as first-line chemotherapy for metastatic breast cancer: Final results of a phase III randomized trial
-
Kaufman PA, Harris R, Skillings J, et al: Losoxantrone + paclitaxel vs paclitaxel alone as first-line chemotherapy for metastatic breast cancer: Final results of a phase III randomized trial (abstract). Proc Am Soc Clin Oncol 17:124a, 1998.
-
(1998)
Proc Am Soc Clin Oncol
, vol.17
-
-
Kaufman, P.A.1
Harris, R.2
Skillings, J.3
-
29
-
-
0001452492
-
Activity of weekly Taxotere in patients with metastatic breast cancer
-
Loeffler TM, Freund W, Droege C, et al: Activity of weekly Taxotere in patients with metastatic breast cancer (abstract). Proc Am Soc Clin Oncol 17:113a, 1998.
-
(1998)
Proc Am Soc Clin Oncol
, vol.17
-
-
Loeffler, T.M.1
Freund, W.2
Droege, C.3
-
30
-
-
0000677325
-
Taxotere vs methotrexate-5-fluorouracil in patients with advanced anthracycline-resistant breast cancer: Preliminary results of a randomized phase III study by Scandinavian Breast Cancer Group
-
Sjöström J, Mouridsen H, Pluzanska A, et al: Taxotere vs methotrexate-5-fluorouracil in patients with advanced anthracycline-resistant breast cancer: Preliminary results of a randomized phase III study by Scandinavian Breast Cancer Group (abstract). Proc Am Soc Clin Oncol 17:111a, 1998.
-
(1998)
Proc Am Soc Clin Oncol
, vol.17
-
-
Sjöström, J.1
Mouridsen, H.2
Pluzanska, A.3
-
31
-
-
0000972173
-
A multicenter phase II trial of Xeloda (capecitabine) in paclitaxel-refractory metastatic breast cancer
-
Blum JL, Buzdar AU, LoRusso PM, et al: A multicenter phase II trial of Xeloda (capecitabine) in paclitaxel-refractory metastatic breast cancer (abstract). Proc Am Soc Clin Oncol 17:125a, 1998.
-
(1998)
Proc Am Soc Clin Oncol
, vol.17
-
-
Blum, J.L.1
Buzdar, A.U.2
LoRusso, P.M.3
-
32
-
-
0000709431
-
A randomized phase II study of Xeloda (capecitabine) vs CMF as first-line chemotherapy of breast cancer in women aged ≥ 55 years (abstract)
-
O' Shaughnessy J, Moiseyenko V, Bell D, et al: A randomized phase II study of Xeloda (capecitabine) vs CMF as first-line chemotherapy of breast cancer in women aged ≥ 55 years (abstract). Proc Am Soc Clin Oncol 17:103a, 1998.
-
(1998)
Proc Am Soc Clin Oncol
, vol.17
-
-
O' Shaughnessy, J.1
Moiseyenko, V.2
Bell, D.3
-
33
-
-
0001432831
-
A randomized phase II study of Xeloda (capecitabine) vs paclitaxel in breast cancer patients failing previous anthracycline therapy (abstract)
-
O' Reilly SM, Moiseyenko V, Talbot DC, et al: A randomized phase II study of Xeloda (capecitabine) vs paclitaxel in breast cancer patients failing previous anthracycline therapy (abstract). Proc Am Soc Clin Oncol 17:163a, 1998.
-
(1998)
Proc Am Soc Clin Oncol
, vol.17
-
-
O' Reilly, S.M.1
Moiseyenko, V.2
Talbot, D.C.3
-
34
-
-
4244031466
-
Synergistic efficacy of Xeloda (capecitabine), a new oral tumor-activated fluoropyrimidine carbamate in combination with taxanes and with 2′-deoxy-2′-methylidenecytidine
-
Ishikawa T, Sawada N, Sekiguchi F, et al: Synergistic efficacy of Xeloda (capecitabine), a new oral tumor-activated fluoropyrimidine carbamate in combination with taxanes and with 2′-deoxy-2′-methylidenecytidine (abstract). Proc Am Soc Clin Oncol 17:244a, 1998.
-
(1998)
Proc Am Soc Clin Oncol
, vol.17
-
-
Ishikawa, T.1
Sawada, N.2
Sekiguchi, F.3
-
35
-
-
0001293608
-
Decreased cardiac toxicity by TLC D-99 (liposome encapsulated doxorubicin) vs doxorubicin in a randomized trial of metastatic breast carcinoma
-
Batist G, Winer E, Navari R, et al: Decreased cardiac toxicity by TLC D-99 (liposome encapsulated doxorubicin) vs doxorubicin in a randomized trial of metastatic breast carcinoma (abstract). Proc Am Soc Clin Oncol 17:115a, 1998.
-
(1998)
Proc Am Soc Clin Oncol
, vol.17
-
-
Batist, G.1
Winer, E.2
Navari, R.3
-
36
-
-
0004570541
-
Phase II randomized study of BMS-182248-1 (BR96-doxorubicin immunoconjugate) vs single-agent doxorubicin in patients with metastatic breast cancer
-
Tolcher A, Sugarman S, Gelmon K: Phase II randomized study of BMS-182248-1 (BR96-doxorubicin immunoconjugate) vs single-agent doxorubicin in patients with metastatic breast cancer (abstract). Proc Am Soc Clin Oncol 17:113a, 1998.
-
(1998)
Proc Am Soc Clin Oncol
, vol.17
-
-
Tolcher, A.1
Sugarman, S.2
Gelmon, K.3
-
37
-
-
0001045163
-
Phase II study of MTA (LY 231514) in patients with locally recurrent or metastatic breast cancer
-
Lind MJ, Smith IE, Coleman RE: Phase II study of MTA (LY 231514) in patients with locally recurrent or metastatic breast cancer (abstract). Proc Am Soc Clin Oncol 17:112a, 1998.
-
(1998)
Proc Am Soc Clin Oncol
, vol.17
-
-
Lind, M.J.1
Smith, I.E.2
Coleman, R.E.3
-
38
-
-
0002529003
-
A phase I study of marimistat in combination with doxorubicin and cyclophosphamide in patients with metastatic breast cancer
-
Gradishar W, Sparano J, Cobleigh M, et al: A phase I study of marimistat in combination with doxorubicin and cyclophosphamide in patients with metastatic breast cancer (abstract). Proc Am Soc Clin Oncol 17:144a, 1998.
-
(1998)
Proc Am Soc Clin Oncol
, vol.17
-
-
Gradishar, W.1
Sparano, J.2
Cobleigh, M.3
-
39
-
-
50549123220
-
On the treatment of inoperable cases of carcinomas of the mamma: Suggestions for a new method of treatment, with illustrative cases
-
Beatson GT: On the treatment of inoperable cases of carcinomas of the mamma: Suggestions for a new method of treatment, with illustrative cases. Lancet 2:104, 1896.
-
(1896)
Lancet
, vol.2
, pp. 104
-
-
Beatson, G.T.1
-
40
-
-
0031054478
-
Tamoxifen as initial endocrine therapy for metastatic breast cancer: Long-term follow-up of two Piedmont Oncology Association (POA) trials
-
Kuss JT, Muss HB, Hoen H, et al: Tamoxifen as initial endocrine therapy for metastatic breast cancer: Long-term follow-up of two Piedmont Oncology Association (POA) trials. Breast Cancer Res Treat 42:265-274, 1997.
-
(1997)
Breast Cancer Res Treat
, vol.42
, pp. 265-274
-
-
Kuss, J.T.1
Muss, H.B.2
Hoen, H.3
-
41
-
-
0020659444
-
Evaluation of tamoxifen doses with and without fluoxymesterone in advanced breast cancer
-
Tormey DC, Lippman ME, Edwards BK, et al: Evaluation of tamoxifen doses with and without fluoxymesterone in advanced breast cancer. Ann Intern Med 98:139-144, 1983.
-
(1983)
Ann Intern Med
, vol.98
, pp. 139-144
-
-
Tormey, D.C.1
Lippman, M.E.2
Edwards, B.K.3
-
42
-
-
0015915672
-
Anti-oestrogen therapy for breast cancer: A trial of tamoxifen at two dose levels
-
Ward HW: Anti-oestrogen therapy for breast cancer: A trial of tamoxifen at two dose levels. Br Med J 1:13-14, 1973.
-
(1973)
Br Med J
, vol.1
, pp. 13-14
-
-
Ward, H.W.1
-
43
-
-
0021141476
-
A comparison of two doses of tamoxifen (Nolvadex) in postmenopausal women with advanced breast cancer: 10 mg bid vs 20 mg bid
-
Bratherton DG, Brown CH, Buchanan R, et al: A comparison of two doses of tamoxifen (Nolvadex) in postmenopausal women with advanced breast cancer: 10 mg bid vs 20 mg bid. Br J Cancer 50:199-205, 1984.
-
(1984)
Br J Cancer
, vol.50
, pp. 199-205
-
-
Bratherton, D.G.1
Brown, C.H.2
Buchanan, R.3
-
44
-
-
0021269031
-
Venous thrombosis as a side effect of tamoxifen treatment
-
Lipton A, Harvey HA, Hamilton RW: Venous thrombosis as a side effect of tamoxifen treatment. Cancer Treat Rep 68:887-889, 1984.
-
(1984)
Cancer Treat Rep
, vol.68
, pp. 887-889
-
-
Lipton, A.1
Harvey, H.A.2
Hamilton, R.W.3
-
45
-
-
0020398315
-
Tamoxifen and oophorectomy in the treatment of recurrent breast cancer: A Southwest Oncology Group study
-
Hoogstraten B, Fletcher WS, Gad-el-Mawla N, et al: Tamoxifen and oophorectomy in the treatment of recurrent breast cancer: A Southwest Oncology Group study. Cancer Res 42:4788-4791, 1982.
-
(1982)
Cancer Res
, vol.42
, pp. 4788-4791
-
-
Hoogstraten, B.1
Fletcher, W.S.2
Gad-El-Mawla, N.3
-
46
-
-
0022617734
-
Randomized trial of bilateral oophorectomy vs tamoxifen in premenopausal women with metastatic breast cancer
-
Ingle JN, Krook JE, Green SJ, et al: Randomized trial of bilateral oophorectomy vs tamoxifen in premenopausal women with metastatic breast cancer. J Clin Oncol 4:178-185, 1986.
-
(1986)
J Clin Oncol
, vol.4
, pp. 178-185
-
-
Ingle, J.N.1
Krook, J.E.2
Green, S.J.3
-
47
-
-
0022554059
-
A randomized comparison of tamoxifen with surgical oophorectomy in premenopausal patients with advanced breast cancer
-
Buchanan RB, Blarney RW, Durrant KR, et al: A randomized comparison of tamoxifen with surgical oophorectomy in premenopausal patients with advanced breast cancer. J Clin Oncol 4:1326-1330, 1986.
-
(1986)
J Clin Oncol
, vol.4
, pp. 1326-1330
-
-
Buchanan, R.B.1
Blarney, R.W.2
Durrant, K.R.3
-
48
-
-
0030787363
-
A randomized crossover trial of tamoxifen vs ovarian ablation for metastatic breast cancer in premenopausal women: A report of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial MA. 1
-
Sawka CA, Pritchard KI, Shelley W, et al: A randomized crossover trial of tamoxifen vs ovarian ablation for metastatic breast cancer in premenopausal women: A report of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial MA. 1. Breast Cancer Res Treat 44:211-215, 1997.
-
(1997)
Breast Cancer Res Treat
, vol.44
, pp. 211-215
-
-
Sawka, C.A.1
Pritchard, K.I.2
Shelley, W.3
-
49
-
-
0030876075
-
An individual patient-based meta-analysis of tamoxifen vs ovarian ablation as first-line endocrine therapy for premenopausal women with metastatic breast cancer
-
Crump M, Sawka CA, DeBoer G, et al: An individual patient-based meta-analysis of tamoxifen vs ovarian ablation as first-line endocrine therapy for premenopausal women with metastatic breast cancer. Breast Cancer Res Treat 44:201-210, 1997.
-
(1997)
Breast Cancer Res Treat
, vol.44
, pp. 201-210
-
-
Crump, M.1
Sawka, C.A.2
DeBoer, G.3
-
50
-
-
0028274195
-
Ovarian ablation vs goserelin with or without tamoxifen in pre-perimenopausal patients with advanced breast cancer: Results of a multicentric Italian study
-
Boccardo F, Rubagotti A, Perrotta A, et al: Ovarian ablation vs goserelin with or without tamoxifen in pre-perimenopausal patients with advanced breast cancer: Results of a multicentric Italian study. Ann Oncol 5:337-342, 1994.
-
(1994)
Ann Oncol
, vol.5
, pp. 337-342
-
-
Boccardo, F.1
Rubagotti, A.2
Perrotta, A.3
-
51
-
-
0031471007
-
Acquired tamoxifen resistance in human breast cancer - Potential mechanisms and clinical implications
-
Johnston SR: Acquired tamoxifen resistance in human breast cancer - potential mechanisms and clinical implications. Anticancer Drugs 8:911-930, 1997.
-
(1997)
Anticancer Drugs
, vol.8
, pp. 911-930
-
-
Johnston, S.R.1
-
53
-
-
0031962302
-
Tamoxifen and toremifene in breast cancer: Comparison of safety and efficacy
-
Buzdar AU, Hortobagyi GN: Tamoxifen and toremifene in breast cancer: Comparison of safety and efficacy. J Clin Oncol 16:348-353, 1998.
-
(1998)
J Clin Oncol
, vol.16
, pp. 348-353
-
-
Buzdar, A.U.1
Hortobagyi, G.N.2
-
54
-
-
2642657654
-
Comparison of toremifene and tamoxifen in postmenopausal patients with advanced breast cancer: A randomized double-blind, the 'Nordic' phase III study
-
Pyrhonen S, Valavaara R, Modig H, et al: Comparison of toremifene and tamoxifen in postmenopausal patients with advanced breast cancer: A randomized double-blind, the 'Nordic' phase III study. Br J Cancer 76:270-277, 1997.
-
(1997)
Br J Cancer
, vol.76
, pp. 270-277
-
-
Pyrhonen, S.1
Valavaara, R.2
Modig, H.3
-
55
-
-
0029084658
-
Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer
-
Hayes DF, Van Zyl JA, Hacking A, et al: Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer. J Clin Oncol 13:2556-2566, 1995.
-
(1995)
J Clin Oncol
, vol.13
, pp. 2556-2566
-
-
Hayes, D.F.1
Van Zyl, J.A.2
Hacking, A.3
-
56
-
-
0030993064
-
High-dose toremifene vs tamoxifen in postmenopausal advanced breast cancer
-
Gershanovich M, Hayes DF, Ellmen J, et al: High-dose toremifene vs tamoxifen in postmenopausal advanced breast cancer. Oncology 11:29-36, 1997.
-
(1997)
Oncology
, vol.11
, pp. 29-36
-
-
Gershanovich, M.1
Hayes, D.F.2
Ellmen, J.3
-
57
-
-
0027463002
-
Toremifene and tamoxifen in advanced breast cancer - A double-blind cross-over trial
-
Stenbygaard LE, Herrstedt J, Thomsen JF, et al: Toremifene and tamoxifen in advanced breast cancer - A double-blind cross-over trial. Breast Cancer Res Treat 25:57-63, 1993.
-
(1993)
Breast Cancer Res Treat
, vol.25
, pp. 57-63
-
-
Stenbygaard, L.E.1
Herrstedt, J.2
Thomsen, J.F.3
-
58
-
-
0026763121
-
Droloxifene, a new anti-oestrogen in postmenopausal advanced breast cancer: Preliminary results of a double-blind dose-finding phase II trial
-
Bruning PF: Droloxifene, a new anti-oestrogen in postmenopausal advanced breast cancer: Preliminary results of a double-blind dose-finding phase II trial. Eur J Cancer 28A:1404-1407, 1992.
-
(1992)
Eur J Cancer
, vol.28 A
, pp. 1404-1407
-
-
Bruning, P.F.1
-
59
-
-
0026337142
-
European early phase II dose-finding study of droloxifene in advanced breast cancer
-
Bellmunt J, Sole L: European early phase II dose-finding study of droloxifene in advanced breast cancer. Am J Clin Oncol 14 (suppl 2):S36-39, 1991.
-
(1991)
Am J Clin Oncol
, vol.14
, Issue.2 SUPPL.
-
-
Bellmunt, J.1
Sole, L.2
-
60
-
-
0030016280
-
Pharmacokinetics, pharmacological and anti-tumour effects of the specific anti-oestrogen ICI 182780 in women with advanced breast cancer
-
Howell A, DeFriend DJ, Robertson JF, et al: Pharmacokinetics, pharmacological and anti-tumour effects of the specific anti-oestrogen ICI 182780 in women with advanced breast cancer. Br J Cancer 74:300-308, 1996.
-
(1996)
Br J Cancer
, vol.74
, pp. 300-308
-
-
Howell, A.1
DeFriend, D.J.2
Robertson, J.F.3
-
61
-
-
0002258194
-
Raloxifene reduces the risk of breast cancer and may decrease the risk of endometrial cancer in post-menopausal women: Two-year findings from the Multiple Outcomes of Raloxifene Evaluation (MORE) trial
-
Cummings SR, Norton L, Eckert S, et al: Raloxifene reduces the risk of breast cancer and may decrease the risk of endometrial cancer in post-menopausal women: Two-year findings from the Multiple Outcomes of Raloxifene Evaluation (MORE) trial (abstract). Proc Am Soc Clin Oncol 17:2a, 1998.
-
(1998)
Proc Am Soc Clin Oncol
, vol.17
-
-
Cummings, S.R.1
Norton, L.2
Eckert, S.3
-
62
-
-
0025036312
-
Second-line hormonal therapy with aminoglutethimide in metastatic breast cancer
-
Brufman G, Biran S: Second-line hormonal therapy with aminoglutethimide in metastatic breast cancer. Acta Oncol 29:717-720, 1990.
-
(1990)
Acta Oncol
, vol.29
, pp. 717-720
-
-
Brufman, G.1
Biran, S.2
-
63
-
-
9244245282
-
A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer
-
Jonat W, Howell A, Blomqvist C, et al: A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer. Eur J Cancer 32A:404-412, 1996.
-
(1996)
Eur J Cancer
, vol.32 A
, pp. 404-412
-
-
Jonat, W.1
Howell, A.2
Blomqvist, C.3
-
64
-
-
0031054095
-
A phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma: Arimidex Study Group
-
Buzdar AU, Jones SE, Vogel CL, et al: A phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma: Arimidex Study Group. Cancer 79:730-739, 1997.
-
(1997)
Cancer
, vol.79
, pp. 730-739
-
-
Buzdar, A.U.1
Jones, S.E.2
Vogel, C.L.3
-
65
-
-
0032530988
-
Anastrozole vs megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: Results of a survival update based on a combined analysis of data from two mature phase III trials: Arimidex Study Group
-
Buzdar AU, Jonat W, Howell A, et al: Anastrozole vs megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: Results of a survival update based on a combined analysis of data from two mature phase III trials: Arimidex Study Group. Cancer 83:1142-1152, 1998.
-
(1998)
Cancer
, vol.83
, pp. 1142-1152
-
-
Buzdar, A.U.1
Jonat, W.2
Howell, A.3
-
66
-
-
0031943424
-
Letrozole, a new oral aromatase inhibitor for advanced breast cancer: Double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate
-
Dombernowsky P, Smith I, Falkson G, et al: Letrozole, a new oral aromatase inhibitor for advanced breast cancer: Double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 16:453-461, 1998.
-
(1998)
J Clin Oncol
, vol.16
, pp. 453-461
-
-
Dombernowsky, P.1
Smith, I.2
Falkson, G.3
-
67
-
-
0038478620
-
First-line fadrozole HCI (CGS 16949A) vs tamoxifen in postmenopausal women with advanced breast cancer: Prospective randomised trial of the Swiss Group for Clinical Cancer Research SAKK 20/88
-
Thurlimann B, Beretta K, Bacchi M, et al: First-line fadrozole HCI (CGS 16949A) vs tamoxifen in postmenopausal women with advanced breast cancer: Prospective randomised trial of the Swiss Group for Clinical Cancer Research SAKK 20/88. Ann Oncol 7:471-479, 1996.
-
(1996)
Ann Oncol
, vol.7
, pp. 471-479
-
-
Thurlimann, B.1
Beretta, K.2
Bacchi, M.3
-
68
-
-
0029940269
-
Fadrozole HCL (CGS-16949A) versus megestrol acetate treatment of postmenopausal patients with metastatic breast carcinoma: Results of two randomized double blind controlled multiinstitutional trials
-
Buzdar AU, Smith R, Vogel C, et al: Fadrozole HCL (CGS-16949A) versus megestrol acetate treatment of postmenopausal patients with metastatic breast carcinoma: Results of two randomized double blind controlled multiinstitutional trials. Cancer 77:2503-2513, 1996.
-
(1996)
Cancer
, vol.77
, pp. 2503-2513
-
-
Buzdar, A.U.1
Smith, R.2
Vogel, C.3
-
69
-
-
0003354802
-
Vorozole vs Megace in postmenopausal patients with metastatic breast carcinoma who had relapsed following tamoxifen
-
Goss P, Wine E, Tannock I, et al: Vorozole vs Megace in postmenopausal patients with metastatic breast carcinoma who had relapsed following tamoxifen (abstract). Proc Am Soc Clin Oncol 16:A542, 1997.
-
(1997)
Proc Am Soc Clin Oncol
, vol.16
-
-
Goss, P.1
Wine, E.2
Tannock, I.3
-
70
-
-
0343924363
-
Formestane vs megestrol acetate in postmenopausal breast cancer patients after failure of tamoxifen: A phase III prospective randomised cross over trial of second-line hormonal treatment (SAKK 20/90): Swiss Group for Clinical Cancer Research (SAKK)
-
Thurlimann B, Castiglione M, Hsu-Schmitz SF, et al: Formestane vs megestrol acetate in postmenopausal breast cancer patients after failure of tamoxifen: A phase III prospective randomised cross over trial of second-line hormonal treatment (SAKK 20/90): Swiss Group for Clinical Cancer Research (SAKK). Eur J Cancer 33:1017-1024, 1997.
-
(1997)
Eur J Cancer
, vol.33
, pp. 1017-1024
-
-
Thurlimann, B.1
Castiglione, M.2
Hsu-Schmitz, S.F.3
-
71
-
-
0029739075
-
Phase II study of the progesterone antagonist mifepristone in patients with untreated metastatic breast carcinoma: A National Cancer Institute of Canada Clinical Trials Group study
-
Perrault D, Eisenhauer EA, Pritchard KI, et al: Phase II study of the progesterone antagonist mifepristone in patients with untreated metastatic breast carcinoma: A National Cancer Institute of Canada Clinical Trials Group study. J Clin Oncol 14:2709-2712, 1996.
-
(1996)
J Clin Oncol
, vol.14
, pp. 2709-2712
-
-
Perrault, D.1
Eisenhauer, E.A.2
Pritchard, K.I.3
-
72
-
-
0026025755
-
Growth factors in development, transformation, and tumorigenesis
-
Cross M, Dexter TM: Growth factors in development, transformation, and tumorigenesis. Cell 64:271-80, 1991.
-
(1991)
Cell
, vol.64
, pp. 271-280
-
-
Cross, M.1
Dexter, T.M.2
-
73
-
-
0022588467
-
Similarity of protein encoded by the human c-erb B-2 gene to epidermal growth factor receptor
-
Yamamoto T, Ikawa S, Akiyama T, et al: Similarity of protein encoded by the human c-erb B-2 gene to epidermal growth factor receptor. Nature 319:230-234, 1986.
-
(1986)
Nature
, vol.319
, pp. 230-234
-
-
Yamamoto, T.1
Ikawa, S.2
Akiyama, T.3
-
74
-
-
0022600388
-
The neu oncogene encodes an epidermal growth factor receptor-related protein
-
Bargman CJ, Hung MC, Weinberg RA: The neu oncogene encodes an epidermal growth factor receptor-related protein. Nature 319:226-230, 1986.
-
(1986)
Nature
, vol.319
, pp. 226-230
-
-
Bargman, C.J.1
Hung, M.C.2
Weinberg, R.A.3
-
75
-
-
0024337144
-
Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer
-
Slamon DJ, Godolphin W, Jones LA, et al: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707-712, 1989.
-
(1989)
Science
, vol.244
, pp. 707-712
-
-
Slamon, D.J.1
Godolphin, W.2
Jones, L.A.3
-
76
-
-
37049183697
-
Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene
-
Slamon DJ, Clark GM, Wong SG, et al: Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177-182, 1987.
-
(1987)
Science
, vol.235
, pp. 177-182
-
-
Slamon, D.J.1
Clark, G.M.2
Wong, S.G.3
-
77
-
-
0024360141
-
Her-2/neu oncogene protein and prognosis in breast cancer
-
Tandon AK, Clark GM, Chamness GC, et al: Her-2/neu oncogene protein and prognosis in breast cancer. J Clin Oncol 7: 1120-1128, 1989.
-
(1989)
J Clin Oncol
, vol.7
, pp. 1120-1128
-
-
Tandon, A.K.1
Clark, G.M.2
Chamness, G.C.3
-
78
-
-
0026625217
-
Prognostic importance of c-erb B-2 expression in breast cancer
-
Gusterson BA, Gelber RD, Goldhirsch A, et al: Prognostic importance of c-erb B-2 expression in breast cancer. J Clin Oncol 10:1049-1056, 1992.
-
(1992)
J Clin Oncol
, vol.10
, pp. 1049-1056
-
-
Gusterson, B.A.1
Gelber, R.D.2
Goldhirsch, A.3
-
79
-
-
0029991439
-
Phase II study of weekly intravenous recombinant humanized anti-p185 HER2 monoclonal antibody in patients with HER2/neu overexpressing metastatic breast cancer
-
Baselga J, Tripathy D, Mendelsohn J, et al: Phase II study of weekly intravenous recombinant humanized anti-p185 HER2 monoclonal antibody in patients with HER2/neu overexpressing metastatic breast cancer. J Clin Oncol 14:737-744, 1996.
-
(1996)
J Clin Oncol
, vol.14
, pp. 737-744
-
-
Baselga, J.1
Tripathy, D.2
Mendelsohn, J.3
-
80
-
-
0000905158
-
Efficacy and safety of Herceptin (humanized anti-HER2 antibody) as a single agent in 222 women with HER2 overexpression who relapsed following chemotherapy for metastatic breast cancer
-
Cobleigh MA, Vogel CL, Tripathy D, et al: Efficacy and safety of Herceptin (humanized anti-HER2 antibody) as a single agent in 222 women with HER2 overexpression who relapsed following chemotherapy for metastatic breast cancer (abstract). Proc Am Soc Clin Oncol 17:91a, 1998.
-
(1998)
Proc Am Soc Clin Oncol
, vol.17
-
-
Cobleigh, M.A.1
Vogel, C.L.2
Tripathy, D.3
-
81
-
-
0000405942
-
Addition of Herceptin (humanized anti-HER2 antibody) to first-line chemotherapy for HER2 overexpressing metastatic breast cancer markedly increases anticancer activity: A randomized, multinational controlled phase III trial
-
Slamon D, Leyland-Jones B, Shak S, et al: Addition of Herceptin (humanized anti-HER2 antibody) to first-line chemotherapy for HER2 overexpressing metastatic breast cancer markedly increases anticancer activity: A randomized, multinational controlled phase III trial (abstract). Proc Am Soc Clin Oncol 17:98a, 1998.
-
(1998)
Proc Am Soc Clin Oncol
, vol.17
-
-
Slamon, D.1
Leyland-Jones, B.2
Shak, S.3
-
82
-
-
0032127350
-
Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts
-
Baselga J, Norton L, Albanell J, et al: Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res 58: 2825-2831, 1998.
-
(1998)
Cancer Res
, vol.58
, pp. 2825-2831
-
-
Baselga, J.1
Norton, L.2
Albanell, J.3
-
83
-
-
0003304702
-
Characterization of cardiac dysfunction observed in the Herceptin (trastuzumab) clinical trials
-
Hudis C, Seidman A, Paton V, et al: Characterization of cardiac dysfunction observed in the Herceptin (trastuzumab) clinical trials (abstract). Breast Cancer Res Treat 50(3):232, 1998.
-
(1998)
Breast Cancer Res Treat
, vol.50
, Issue.3
, pp. 232
-
-
Hudis, C.1
Seidman, A.2
Paton, V.3
-
84
-
-
0019847618
-
Tamoxifen vs aminoglutethimide in advanced breast carcinoma: A randomized cross-over trial
-
Smith IE, Harris AL, Morgan M, et al: Tamoxifen vs aminoglutethimide in advanced breast carcinoma: A randomized cross-over trial. Br J Med 283:1432-1434, 1981.
-
(1981)
Br J Med
, vol.283
, pp. 1432-1434
-
-
Smith, I.E.1
Harris, A.L.2
Morgan, M.3
-
85
-
-
0019382847
-
Randomized clinical trial of diethylstilbestrol vs tamoxifen in postmenopausal women with advanced breast cancer
-
Ingle JN, Ahmann DL, Green SJ, et al: Randomized clinical trial of diethylstilbestrol vs tamoxifen in postmenopausal women with advanced breast cancer. N Engl J Med 304:16-21, 1981.
-
(1981)
N Engl J Med
, vol.304
, pp. 16-21
-
-
Ingle, J.N.1
Ahmann, D.L.2
Green, S.J.3
-
86
-
-
85036438369
-
Tamoxifen vs high-dose oral medroxyprogesterone acetate as initial endocrine therapy for patients with metastatic breast cancer: A Piedmont Oncology Association study
-
Muss HB, Case LD, Atkins JN, et al: Tamoxifen vs high-dose oral medroxyprogesterone acetate as initial endocrine therapy for patients with metastatic breast cancer: A Piedmont Oncology Association study. J Clin Oncol 6:1098-1106, 1988.
-
(1988)
J Clin Oncol
, vol.6
, pp. 1098-1106
-
-
Muss, H.B.1
Case, L.D.2
Atkins, J.N.3
-
87
-
-
0024041157
-
Megestrol acetate versus tamoxifen in advanced breast cance, 5-year analysis - A phase III trial of the Piedmont Oncology Association
-
Muss HB, Wells HB, Paschold EH, et al: Megestrol acetate versus tamoxifen in advanced breast cance, 5-year analysis - a phase III trial of the Piedmont Oncology Association. J Clin Oncol 6:1098-1106, 1988.
-
(1988)
J Clin Oncol
, vol.6
, pp. 1098-1106
-
-
Muss, H.B.1
Wells, H.B.2
Paschold, E.H.3
-
88
-
-
0028131860
-
Comparison of the selective aromatase inhibitor formestane with tamoxifen as first-line hormonal therapy in postmenopausal women with advanced breast cancer
-
Perez Carrion R, Alberola Candel V, Calabresi F, et al: Comparison of the selective aromatase inhibitor formestane with tamoxifen as first-line hormonal therapy in postmenopausal women with advanced breast cancer. Ann Oncol 5 (suppl 7):S19-24, 1994.
-
(1994)
Ann Oncol
, vol.5
, Issue.7 SUPPL.
-
-
Perez Carrion, R.1
Alberola Candel, V.2
Calabresi, F.3
|